How did SAGE's Q1 2024 EPS outperform forecasts?
4/5/2025 02:12pm
Sage Therapeutics' (SAGE) Q1 2024 EPS fell short of forecasts by $0.15, reflecting a challenging period for the company. The EPS of -$1.8 represents a significant decline from the expected figure, indicating that the company faced unexpected difficulties during the quarter.
|code|Ticker|Name|Date|EPS Surprise|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|SAGE|SAGE.O|Sage Therapeutics|2023 Q2|-0.13|-2.68|185|
|SAGE|SAGE.O|Sage Therapeutics|2023 Q3|-0.64|-3.37|185|
|SAGE|SAGE.O|Sage Therapeutics|2023 Q4|0.73||185|
|SAGE|SAGE.O|Sage Therapeutics|2024 Q1|-0.15|-1.8|185|